Leslye G. Katz
Known title: DirectorCIK: 0001193884
Associated companies
Transaction History
| EHC | ▲ Buy | Grant | 85 | $0 | 7/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 1,634 | $0 | 5/7/2026 | View on chart |
| EHC | ▲ Buy | Grant | 85 | $0 | 4/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 87 | $0 | 1/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 73 | $0 | 10/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 74 | $0 | 7/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 1,424 | $0 | 5/1/2025 | View on chart |
| EHC | ▲ Buy | Grant | 76 | $0 | 4/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 83 | $0 | 1/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 81 | $0 | 10/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 80 | $0 | 7/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 1,978 | $0 | 5/2/2024 | View on chart |
| EHC | ▲ Buy | Grant | 80 | $0 | 4/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 91 | $0 | 1/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 101 | $0 | 10/16/2023 | View on chart |
| EHC | ▲ Buy | Grant | 95 | $0 | 7/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 2,385 | $0 | 5/4/2023 | View on chart |
| EHC | ▲ Buy | Grant | 99 | $0 | 4/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 99 | $0 | 1/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 123 | $0 | 10/17/2022 | View on chart |
| EHC | ▲ Buy | Grant | 226 | $0 | 7/20/2022 | View on chart |
| EHC | ▲ Buy | Grant | 2,226 | $0 | 5/5/2022 | View on chart |
| EHC | ▲ Buy | Grant | 121 | $0 | 4/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 139 | $0 | 1/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 126 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.